Buddyboy,

Nice find.

While I don't want to be too snarky, it is mildly amusing that the google translation from an obscure Chine pharmaceutical website is more comprehensible than some of the press releases.

Nonetheless, the translation reads:

Quote:

---

CCR5 is a receptor of intracellular beta chemokine (RANTES, MIP1α and MIP1β). It has the function of regulating the migration, proliferation and immunity of T cells and mononuclear cells/giant eophil lines. It is mainly expressed on the cell membrane of T lymphocytes, mononuclear cells and immature dendritic cells.

Cancer research shows that CCR5 may play a role in tumor invasion, metastasis and tumor microenvironment control (for example, through angiogenesis). Published studies have shown that blocking CCR5 can reduce tumor metastasis in laboratory and animal models of invasive breast and prostate cancer.

Leronlimab(PRO140) is a humanized IgG4 monoclonal antibody that can target block chemokine receptor 5 (CCR5). At present, the FDA has awarded the fast-track certification of the CCR5 antagonist leronlimab (PRO140) for the treatment of CCR5-positive metastatic triple negative breast cancer patients in combination with carboplatin.

The determination is based on the experimental results of 28 patients with metastatic triple negative breast cancer. These patients have received at least 2 treatments and failed before receiving Leronlimab's treatment.
These patients came from 3 clinical trials (NCT04313075, NCT03838367 and one basket test), all of which were stage IV metastatic triple negative breast cancer. Before receiving treatment, 61% of patients had visceral metastasis, 75% of patients had brain metastasis, and 11% had bone metastasis.
The test results showed that the median total survival period (mOS) of patients receiving Leronlimab treatment exceeded 12 months! It is significantly better than SOC chemotherapy group (6.6 months) or SacituzumabGovitecan (SG) group (11.8 months).

In terms of non-progressive survival (mPFS), mPFS for patients receiving higher doses (≥525mg) Leronlimab combined chemotherapy was 6.2 months (95%CI, 2.6–7.5 months), compared with SOC chemotherapy (2.3 months) and SG (4.8 months). The median progression-free survival period has also been significantly extended.
In terms of response rate, Leronlimab's performance was also stable, with a disease control rate of 92%.

At present, the drug is undergoing two clinical trials, one is mTNBC's 1b/2 test, which was awarded a fast-track designation by the FDA in 2019 and the second is a 2-phase basket test including 22 different solid tumor cancers.

---

https://www.pd1.cn/zhongliufenlei/ruxianai/12898.html